We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hep C Race: Gilead Gets Poor Results, Novartis Jumps Into Game
Hep C Race: Gilead Gets Poor Results, Novartis Jumps Into Game
February 29, 2012
Gilead has stumbled in the ongoing hepatitis C race with the relapse of most patients in one trial arm just a few weeks after ending treatment with GS-7977 — a recent pipeline acquisition.